|Bid||10.50 x 1100|
|Ask||10.60 x 1100|
|Day's range||10.15 - 10.87|
|52-week range||10.15 - 121.98|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||N/A|
|Earnings date||29 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||64.57|
The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again.
If you want to know who really controls Cortexyme, Inc. ( NASDAQ:CRTX ), then you'll have to look at the makeup of its...
Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward.